This site is intended for health professionals only

Matrix’s Lansoprazole approved

teaser

Mylan’s Indian subsidiary Matrix Laboratories has received US Food and Drug Administration (FDA) approval for its Lansoprazole delayed-release capsules.

They are a generic version of Tap Pharmaceuticals’ Prevacid proton pump inhibitor capsules, which had US sales of $3 billion for the 12 months ending June 30.

Mylan reportedly has 125 abbreviated new drug applications (ANDAs) pending approval, which represent $84 billion in annual brand sales. Of these, 37 are potential first-to-file applications worth $19 billion a year.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Mylan is a world-ranking generic pharmaceutical company selling into 140 countries and territories. It has one of the industry’s broadest product portfolios and is the third-largest drug manufacturer, including respiratory and allergy treatments.

Copyright Press Association 2009

Lansoprazole






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x